L-arginine
This article was originally published in The Tan Sheet
Executive Summary
"L-arginine therapy should not be given to patients following a myocardial infarction," a study in the Jan. 4 Journal of the American Medical Association concludes. Adding the supplement to standard post-MI drug therapy "did not reduce noninvasive measures of vascular stiffness, improve ejection fraction, or improve clinical outcomes," Steven Schulman, MD, Johns Hopkins Medical Institutions, et al., state. "We noted a possible increased risk of death in older patients after infarction while taking L-arginine compared with those taking a placebo." The randomized, double-blind, placebo-controlled trial was terminated early after the deaths of six patients in the L-arginine group. Increased risk of death in older patients may be due to age-related cardiovascular changes, such as endothelial dysfunction, the authors note...
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.